Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. .

Trials 130

Trials FDA Immune Response Clinical Trials 130

Drug Discovery World

JANUARY 17, 2023

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital. . The trial . The primary criteria is PFS.

Clinical Trials 130

Clinical Trials Trials Drug Development Hospitals 130

Drug Discovery World

MARCH 24, 2023

dendritic cells, monocytes) triggers a broad immune response that includes significant increases in cytotoxic CD8 plus T cells armed with chemo-induced tumour antigens to target cancer. This synergy was demonstrated by the AIPAC Phase IIb trial’s encouraging efficacy and safety, including a over 2.9-month

Trials 130

Trials Immune Response FDA Clinical Development 130

Drug Discovery World

FEBRUARY 24, 2023

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The trial also evaluated the efficacy of HTI vaccines in combination with VES to avoid, delay or contain viral rebound compared to a placebo group.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Drug Target Review

JANUARY 15, 2024

Research 1 has shown that neutrophil elastase selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilises adaptive immunity, and avoids resistance mechanisms. Could you provide insights into the driving factors behind exploring novel treatments for cancer types?

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

Olympian Clinical Research

MAY 6, 2024

The journey toward effective treatments has been long and evolving, with recent breakthroughs offering new hope to those living with this challenging condition. From Coal Tar to Biologics: A Historical Perspective The history of psoriasis treatment is as old as the condition itself, with records dating back to ancient times.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

MAY 28, 2024

Professor Trent Woodruff from UQ’s School of Biomedical Sciences said the new approach addressed an underlying cause of organ failure, while previous unsuccessful attempts had focused largely on the immune response.

Immune Response 147

Immune Response Hospitals Drugs Clinical Trials 147

Drug Discovery World

MARCH 26, 2024

It is approved in adults and adolescents (12 years of age and older weighing at least 40kg) who are moderate-to-severely immune compromised due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to Covid-19 vaccination.

FDA Approval 130

FDA Approval FDA Clinical Trials Immune Response 130

Drug Discovery World

APRIL 12, 2024

The top stories: Genetically engineered dendritic cells enhance lung cancer therapy A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.

Immune Response 130

Immune Response Engineering Drugs Therapies 130

Olympian Clinical Research

NOVEMBER 30, 2023

While the journey to understand and treat this condition has been complex, recent innovations in vitiligo treatment have opened new doors, offering hope and improved outcomes for those affected. The Evolution of Vitiligo Treatments From ancient remedies to modern medicine, the treatment of vitiligo has undergone a remarkable transformation.

Treatment 52

Treatment Clinical Research Clinical Trials Immune Response 52

Drug Discovery World

APRIL 3, 2023

This year, the team will launch a combined Phase I and IIa trial of R805/CX-011 for the treatment of osteoarthritis in patients in collaboration with the start-up Carthronix. The post Potentially ‘regenerative’ osteoarthritis drug moves to clinical trial appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials FDA Approval Drugs 130

Drug Discovery World

MAY 23, 2024

The three-year survival rate for children with high-grade gliomas, without further complications, is only 11-22%, and the currently available treatments, radiotherapy and chemotherapy, can harm the child’s developing brain. The virus also increased the number of immunity-boosting white blood cells within the tumours.

Virus 147

Virus Immune Response Vaccine Engineering 147

Drug Discovery World

DECEMBER 16, 2022

The proceeds from the financing will support the ongoing multiple-ascending dose trial of STC-15 and further facilitate Storm as we advance our pipeline of products.” . STC-15 triggers both direct cytotoxic and immune response-based efficacy mechanisms in solid tumour and leukaemia models.

RNA 130

RNA Immune Response Small Molecule Therapies 130

Drug Discovery World

OCTOBER 10, 2023

Read more: Preclinical study proves antidepressant effects of drug Psychedelic-based drug options Later the same month, Cybin announced it had completed dosing in Cohort 5 of a Phase II trial evaluating CYB003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder (MDD).

Immune Response 147

Immune Response Drugs FDA Approval DNA 147

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” This involves the use of CAR-T cell products derived from donor T cells, hence the term “off the shelf,” making it easier to standardise treatments.

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Discovery World

APRIL 16, 2023

The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb KEYNOTE-942 clinical trial presented at the AACR Annual Meeting 2023, held April 14-19. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response.

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

FEBRUARY 28, 2024

According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

JANUARY 3, 2023

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . The commencement of the trial triggers a $5 million milestone payment to RQ Bio and will enable the company to execute its four scientific programmes focused on viral diseases. .

Immune Response 130

Immune Response Clinical Trials Vaccine Licensing 130

Drug Discovery World

APRIL 16, 2023

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The approval was based on results from the TOPAZ-1 clinical trial. months, as compared with 10.9

Clinical Trials 130

Clinical Trials Immune Response Trials Therapies 130

Drug Discovery World

SEPTEMBER 9, 2022

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Patients on the trial had cancers including skin, oesophageal and head and neck cancer and had exhausted other treatments, including by failing to respond to checkpoint inhibitor immunotherapy.

Virus 130

Virus Research Immune Response Engineering 130

Drug Discovery World

NOVEMBER 8, 2022

mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase II clinical trial being conducted by Moderna. . KEYNOTE-942 is an ongoing randomised, open-label Phase II trial that enrolled 157 patients with high-risk melanoma.

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Drug Discovery World

JULY 5, 2023

Precision oncology supports targeted therapeutic treatments by determining the specific molecular characteristics of a tumour – the molecular phenotype, as it’s called – to obtain an in depth understanding of the patient’s unique cancer and using it to specifically target the patient’s cancer on a molecular level.

Research 246

Research Immune Response Pharmaceutical Companies Treatment 246

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. It forms part of the UK Recovery Trial, which found that a cheap steroid called dexamethasone could save lives. We need to know, and the way to know is to do the trials that will tell us whether that hope turns into reality.”.

Trials 52

Trials Immune Response Virus Vaccine 52

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. Triebel saw an opportunity to synergistically combine efti with these checkpoint inhibitors, given its markedly different mechanism of action.

Immune Response 246

Immune Response Therapies Vaccine Production 246

Olympian Clinical Research

NOVEMBER 9, 2022

Therefore, if you or a loved one is dealing with this rare condition, it’s essential to educate yourself about the condition and its potential treatments. This condition is thought to result from the immune system mistakenly attacking a thin layer of tissue below the outer layer of your skin.

Treatment 52

Treatment Clinical Research Immune Response Therapies 52

Drug Discovery World

OCTOBER 7, 2022

The research gives insight into the function of immune cells in patients with chemotherapy-resistant breast cancers. While chemotherapy may not kill cancer cells in these high-risk patients, immunotherapy, a type of treatment that helps the immune system to attack cancer cells, may provide a benefit. .

Research 130

Research Immune Response Bioinformatics Treatment 130

Drug Discovery World

NOVEMBER 10, 2023

CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial of CAN-2409 that showed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC). The estimated overall survival rate was 71.4%

Pharmacokinetics 130

Pharmacokinetics Clinical Trials Immune Response Treatment 130

SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response 88

Immune Response Production Regulations Clinical Trials 88

Drug Discovery World

FEBRUARY 6, 2023

This is part of why patients in trials and the clinic can experience severe toxicity and adverse events, reject their therapy with an immune response, or completely fail to respond to treatment. These technologies in no way recapitulate the proteome that antibodies are tested against within a single human in nature.

Immune Response 130

Immune Response Clinical Trials Drug Development Production 130

Drug Target Review

MAY 14, 2024

Since cancer cells are under chronic stimulation of ER stress, the polypeptides cannot activate innate immune sensors in cancer cells even upon the polypeptide treatment. How did the combination of the polypeptides with immune checkpoint inhibitors affect the antitumour responses in the mouse models?

Engineering 59

Engineering Immune Response FDA Approval DNA 59

Drug Discovery World

FEBRUARY 19, 2024

C-peptide levels reached normal levels and there was no indication that the allogeneic HIP p-islet graft induced any immune recognition or any type of immune response at any time. The post Cell therapy enables insulin independence without immunosuppression appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Immune Response Engineering Trials 130

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About the Phase 1/2/3 Trial in Children. Pfizer Inc.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

Conversations in Drug Development Trends

JUNE 21, 2024

Worldwide Clinical Trials attends each year to hear from the research community, connect with our sponsors and sites, and explore potential partnerships to drive forward novel treatments. Check out this webinar on navigating the landscape of oncology clinical trials. Interested in hearing more insights from Matt?

Clinical Trials 64

Clinical Trials Clinical Research Immune Response Therapies 64

The Pharma Data

DECEMBER 23, 2020

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. This Phase IIa trial follows a preliminary study conducted by Prof.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52